LoRusso P - Search Results

1

Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.

Li J, Kim S, Sha X, Wiegand R, Wu J, LoRusso P. Li J, et al. Among authors: lorusso p. Clin Cancer Res. 2014 Aug 1;20(15):3931-44. doi: 10.1158/1078-0432.CCR-14-0791. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947923 Free PMC article.

2

Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).

Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH. Foster BJ, et al. Among authors: lorusso pm. Invest New Drugs. 1997;15(3):187-94. doi: 10.1023/a:1005846026398. Invest New Drugs. 1997. PMID: 9387041

3

Preclinical anticancer activity of cryptophycin-8.

Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand RA, Lisow L, Golakoti T, Heltzel CE, Ogino J, Patterson GM, Moore RE. Corbett TH, et al. Among authors: lorusso p. J Exp Ther Oncol. 1996 Mar;1(2):95-108. J Exp Ther Oncol. 1996. PMID: 9414393

4

Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.

Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH. Foster BJ, et al. Among authors: lorusso pm. Clin Cancer Res. 1997 Nov;3(11):2047-53. Clin Cancer Res. 1997. PMID: 9815596

5

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).

LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L. LoRusso P, et al. Clin Cancer Res. 1995 Dec;1(12):1487-93. Clin Cancer Res. 1995. PMID: 9815948 Clinical Trial.

6

Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.

Foster BJ, Wiegand RA, LoRusso PM, Baker LH. Foster BJ, et al. Among authors: lorusso pm. Clin Cancer Res. 1995 Aug;1(8):831-7. Clin Cancer Res. 1995. PMID: 9816052

7

Phase I pharmacokinetic study of the novel antitumor agent SR233377.

LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH. LoRusso PM, et al. Clin Cancer Res. 2000 Aug;6(8):3088-94. Clin Cancer Res. 2000. PMID: 10955788 Clinical Trial.

8

The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.

Ding Z, Parchment RE, LoRusso PM, Zhou JY, Li J, Lawrence TS, Sun Y, Wu GS. Ding Z, et al. Among authors: lorusso pm. Clin Cancer Res. 2001 Nov;7(11):3336-42. Clin Cancer Res. 2001. PMID: 11705845

9

A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.

Gadgeel SM, Boinpally RR, Heilbrun LK, Wozniak A, Jain V, Redman B, Zalupski M, Wiegand R, Parchment R, LoRusso PM. Gadgeel SM, et al. Among authors: lorusso pm. Invest New Drugs. 2003 Feb;21(1):63-74. doi: 10.1023/a:1022972427532. Invest New Drugs. 2003. PMID: 12795531 Free article. Clinical Trial.

10

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. LoRusso PM, et al. Clin Cancer Res. 2003 Jun;9(6):2040-8. Clin Cancer Res. 2003. PMID: 12796366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

422 results

Search Page

Filters